NOVARTIS joins the Rare Disease Action Forum as member

    20 Feb, 2020

    In February 2020 Novartis joined the Rare Disease Action Forum (RDAF) as member. With its members coming from industry, patient organizations, Healthcare Professionals and research organizations, the RDAF acts as multi-stakeholder platform in the field of rare diseases. With its increased membership the RDAF reinforces its contribution to improve access to diagnosis, treatment and patient care for patients with rare diseases in Switzerland.

    Continue reading

    RDAF hosts multi-stakeholder workshop on post-marketing registries

    The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...

    RDAF Newsletter

    We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include: Overview of the latest policy developments relevant for the rare disease field...